Analyst Reco. Repligen Corporation

Equities

RGEN

US7599161095

Real-time Estimate Cboe BZX Other stock markets 12:10:05 2024-04-26 pm EDT			5-day change	1st Jan Change
166.8 ^USD	+0.68%		+6.29%	-7.11%

Apr. 08	RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating	MT
Mar. 20	Transcript : Repligen Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-20-2024 03:00 PM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating	Apr. 08	MT
UBS Adjusts Repligen Price Target to $225 From $211, Maintains Buy Rating	Feb. 22	MT
Deutsche Bank Adjusts Repligen Price Target to $180 From $175, Maintains Hold Rating	Feb. 22	MT
RBC Raises Price Target on Repligen to $225 From $200, Keeps Outperform Rating	Feb. 22	MT
Stocks Decline Pre-Bell as Fed Outlook, Rates Weigh; Asia Mixed, Europe Mostly Up	Feb. 21	MT
Deutsche Bank Adjusts Repligen Price Target to $175 From $150, Maintains Hold Rating	Dec. 18	MT
UBS Adjusts Repligen Price Target to $211 From $170, Maintains Buy Rating	Dec. 15	MT
Benchmark Downgrades Repligen to Hold From Buy	Dec. 04	MT
Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating	Nov. 07	MT
CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating	Nov. 03	MT
RBC Trims Price Target on Repligen to $837 From $847, Keeps Sector Perform Rating	Nov. 03	MT
UBS Adjusts Repligen Price Target to $170 From $210, Maintains Buy Rating	Nov. 01	MT
KeyBanc Lowers Price Target on Repligen to $210 From $240, Maintains Overweight Rating	Nov. 01	MT
Craig Hallum Cuts Repligen Price Target to $175 From $200, Maintains Buy Rating	Nov. 01	MT
RBC Cuts Price Target on Repligen to $200 From $207, Keeps Outperform Rating	Nov. 01	MT
JPMorgan Cuts Repligen Price Target to $180 From $200, Maintains Overweight Rating	23-10-17	MT
UBS Adjusts Repligen Price Target to $210 From $199, Maintains Buy Rating	23-08-03	MT
Stephens Adjusts Price Target on Repligen to $200 From $180, Maintains Overweight Rating	23-08-03	MT
RBC Boosts Price Target on Repligen to $195 From $157, Keeps Outperform Rating	23-08-03	MT
Wells Fargo Initiates Coverage on Repligen With Overweight Rating, $185 Price Target	23-07-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Repligen Corporation

Equities

RGEN

US7599161095

Analyst Reco.

Filters